Emerging cancer therapeutic opportunities by inhibiting mitotic kinases
Authors:
- Ignacio Pérez de CastroIgnacio Pérez de Castro
- Guillermo de CárcerGCGuillermo de Cárcer
- Guillermo MontoyaGMGuillermo Montoya
- Marcos MalumbresMMMarcos Malumbres
- 1 August 2008
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 8 (4) , 375-383
Abstract
No abstract availableKeywords
Funding Information
- Comunidad de Madrid (CSD2006-00023, CSD2007-00017, PET2007-0237, S-BIO-0283-2006, S-GEN-0166/2006)
- Association for International Cancer Research (08-0188)
- European Commission (017448-IRG7)
- Association for International Cancer Research
- Ministerio de Educación, Cultura y Deporte
- Albert Einstein Cancer Center
- Ministry of Education and Science (SAF2006-05186, SAF2007-64571)
- Fundación Ramón Areces
This publication has 52 references indexed in Scilit:
- Plx1 is required for chromosomal DNA replication under stressful conditionsThe EMBO Journal, 2008
- CDK inhibitors in cancer therapy: what is next?Trends in Pharmacological Sciences, 2008
- A novel role for the Aurora B kinase in epigenetic marking of silent chromatin in differentiated postmitotic cellsThe EMBO Journal, 2007
- Cdk1 is sufficient to drive the mammalian cell cycleNature, 2007
- Plk4-Induced Centriole Biogenesis in Human CellsDevelopmental Cell, 2007
- HEF1-Dependent Aurora A Activation Induces Disassembly of the Primary CiliumCell, 2007
- The spindle-assembly checkpoint in space and timeNature Reviews Molecular Cell Biology, 2007
- Requirements for Cdk7 in the Assembly of Cdk1/Cyclin B and Activation of Cdk2 Revealed by Chemical Genetics in Human CellsMolecular Cell, 2007
- Cell cycle kinases in cancerCurrent Opinion in Genetics & Development, 2007
- Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1Proceedings of the National Academy of Sciences, 2006